Mizuho Issues Pessimistic Forecast for Inspire Medical Systems (NYSE:INSP) Stock Price

Inspire Medical Systems (NYSE:INSP) had its price target decreased by stock analysts at Mizuho from $70.00 to $55.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s target price would indicate a potential upside of 0.43% from the stock’s previous close.

A number of other research firms have also recently weighed in on INSP. Wells Fargo & Company set a $70.00 price objective on Inspire Medical Systems and gave the stock an “equal weight” rating in a research report on Thursday, February 12th. Truist Financial decreased their price objective on Inspire Medical Systems from $70.00 to $64.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. UBS Group set a $67.00 price objective on Inspire Medical Systems in a research report on Friday, February 13th. Bank of America reaffirmed a “neutral” rating and set a $53.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $56.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, April 14th. Four analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $94.89.

Inspire Medical Systems Stock Down 3.4%

INSP stock opened at $54.77 on Tuesday. The business has a 50 day moving average price of $56.73 and a 200 day moving average price of $79.64. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 2.92 and a beta of 0.83. Inspire Medical Systems has a fifty-two week low of $48.30 and a fifty-two week high of $163.35.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.38. The firm had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, sell-side analysts anticipate that Inspire Medical Systems will post 1.82 EPS for the current year.

Institutional Trading of Inspire Medical Systems

Several hedge funds have recently modified their holdings of the business. Wellington Management Group LLP acquired a new stake in shares of Inspire Medical Systems in the 4th quarter valued at approximately $203,929,000. Wasatch Advisors LP lifted its holdings in shares of Inspire Medical Systems by 7.2% in the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after buying an additional 110,288 shares during the period. William Blair Investment Management LLC lifted its holdings in shares of Inspire Medical Systems by 68.7% in the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock valued at $96,280,000 after buying an additional 528,404 shares during the period. Morgan Stanley lifted its holdings in shares of Inspire Medical Systems by 179.5% in the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after buying an additional 809,121 shares during the period. Finally, Deerfield Management Company L.P. raised its holdings in Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after purchasing an additional 907,694 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 beat on EPS and revenue: Inspire reported $0.10 EPS (vs. expectations for a loss) and $204.6M in revenue, a modest year-over-year increase and slightly above consensus — shows underlying procedure demand held up in the quarter. Read More.
• Neutral Sentiment: Earnings call and details: Management discussed operational drivers and the timing impact of reimbursement/coding headwinds and the WISeR disruption — useful for modeling cadence but contained no offsetting near-term revenue levers. Read More.
• Negative Sentiment: Guidance cut materially lowers FY26 targets: Inspire lowered FY2026 revenue guidance to $825M–$875M and EPS to $0.75–$1.25, well below consensus — the reset is the main driver of the trader reaction and forces downward revisions to FY26 models. Read More.
• Negative Sentiment: Reimbursement/coding and WISeR disruption cited as causes: Management specifically blamed coding changes and disruption related to WISeR (workflow/servicing) for reduced procedure volumes and reimbursement uncertainty — this raises execution and policy risk until coding/reimbursement pathways normalize. Read More.
• Negative Sentiment: Market reaction and coverage: Media and market reports noted the sharp intraday pullback after guidance — highlights how the guidance reset dominated the beat and forced rapid re-pricing. Read More.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.